Repurposing Drugs for Treatment of Age-Related Macular Degeneration.
Adv Exp Med Biol
; 1415: 73-77, 2023.
Article
en En
| MEDLINE
| ID: mdl-37440017
ABSTRACT
The need for new drugs to treat dry forms of age-related macular degeneration remains high. A promising approach is repurposing of FDA-approved medications to treat AMD. Databases containing medical and drug records allow for retroactive identification of drugs whose use correlates with reduced AMD diagnosis. This short review summarizes progress in several classes of drugs considered for repurposing GPR-143 agonists (L-DOPA), anti-diabetic drugs (metformin, acarbose, empagliflozin, fenofibrate), mitochondrial activators (PU-91), and serotonin pathway drugs (fluoxetine, flibanserin, xaliproden, buspirone). The promises and caveats of repurposing are discussed herein.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Degeneración Macular
/
Metformina
Límite:
Humans
Idioma:
En
Revista:
Adv Exp Med Biol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos